2015 Q2 Form 10-Q Financial Statement
#000119312515284946 Filed on August 10, 2015
Income Statement
| Concept | 2015 Q2 | 2014 Q2 |
|---|---|---|
| Revenue | $874.0K | $960.0K |
| YoY Change | -8.96% | -90.37% |
| Cost Of Revenue | ||
| YoY Change | ||
| Gross Profit | ||
| YoY Change | ||
| Gross Profit Margin | ||
| Selling, General & Admin | $1.900M | $1.500M |
| YoY Change | 26.67% | 50.0% |
| % of Gross Profit | ||
| Research & Development | $4.684M | $3.200M |
| YoY Change | 46.38% | 58.34% |
| % of Gross Profit | ||
| Depreciation & Amortization | $200.0K | $190.0K |
| YoY Change | 5.26% | -52.5% |
| % of Gross Profit | ||
| Operating Expenses | $6.606M | $4.672M |
| YoY Change | 41.4% | 52.98% |
| Operating Profit | -$5.732M | -$3.712M |
| YoY Change | 54.42% | -153.65% |
| Interest Expense | $13.00K | $56.00K |
| YoY Change | -76.79% | -103.5% |
| % of Operating Profit | ||
| Other Income/Expense, Net | $13.00K | |
| YoY Change | ||
| Pretax Income | -$5.719M | -$3.656M |
| YoY Change | 56.43% | -168.76% |
| Income Tax | -$35.00K | -$11.00K |
| % Of Pretax Income | ||
| Net Earnings | -$5.684M | -$3.645M |
| YoY Change | 55.94% | -168.3% |
| Net Earnings / Revenue | -650.34% | -379.69% |
| Basic Earnings Per Share | -$0.16 | |
| Diluted Earnings Per Share | -$250.0K | -$0.16 |
| COMMON SHARES | ||
| Basic Shares Outstanding | 22.83M shares | 22.61M shares |
| Diluted Shares Outstanding | 22.83M shares | 22.61M shares |
Balance Sheet
| Concept | 2015 Q2 | 2014 Q2 |
|---|---|---|
| SHORT-TERM ASSETS | ||
| Cash & Short-Term Investments | $43.20M | $62.80M |
| YoY Change | -31.21% | 196.23% |
| Cash & Equivalents | $43.19M | $62.81M |
| Short-Term Investments | ||
| Other Short-Term Assets | $600.0K | $1.700M |
| YoY Change | -64.71% | 1600.0% |
| Inventory | ||
| Prepaid Expenses | ||
| Receivables | ||
| Other Receivables | ||
| Total Short-Term Assets | $44.03M | $65.06M |
| YoY Change | -32.32% | 204.0% |
| LONG-TERM ASSETS | ||
| Property, Plant & Equipment | $1.710M | $2.439M |
| YoY Change | -29.89% | -23.78% |
| Goodwill | ||
| YoY Change | ||
| Intangibles | ||
| YoY Change | ||
| Long-Term Investments | ||
| YoY Change | ||
| Other Assets | $700.0K | $700.0K |
| YoY Change | 0.0% | 0.0% |
| Total Long-Term Assets | $2.410M | $3.139M |
| YoY Change | -23.22% | -19.51% |
| TOTAL ASSETS | ||
| Total Short-Term Assets | $44.03M | $65.06M |
| Total Long-Term Assets | $2.410M | $3.139M |
| Total Assets | $46.44M | $68.19M |
| YoY Change | -31.9% | 169.54% |
| SHORT-TERM LIABILITIES | ||
| YoY Change | ||
| Accounts Payable | $711.0K | $1.191M |
| YoY Change | -40.3% | 32.33% |
| Accrued Expenses | $2.400M | $1.400M |
| YoY Change | 71.43% | 366.67% |
| Deferred Revenue | ||
| YoY Change | ||
| Short-Term Debt | $0.00 | $0.00 |
| YoY Change | -100.0% | |
| Long-Term Debt Due | ||
| YoY Change | ||
| Total Short-Term Liabilities | $3.239M | $5.617M |
| YoY Change | -42.34% | -36.17% |
| LONG-TERM LIABILITIES | ||
| Long-Term Debt | $0.00 | $0.00 |
| YoY Change | ||
| Other Long-Term Liabilities | $700.0K | $1.000M |
| YoY Change | -30.0% | -56.52% |
| Total Long-Term Liabilities | $700.0K | $1.000M |
| YoY Change | -30.0% | -56.52% |
| TOTAL LIABILITIES | ||
| Total Short-Term Liabilities | $3.239M | $5.617M |
| Total Long-Term Liabilities | $700.0K | $1.000M |
| Total Liabilities | $4.000M | $6.600M |
| YoY Change | -39.39% | -40.54% |
| SHAREHOLDERS EQUITY | ||
| Retained Earnings | -$90.57M | -$69.48M |
| YoY Change | 30.35% | |
| Common Stock | $133.0M | $23.00K |
| YoY Change | 578352.17% | |
| Preferred Stock | ||
| YoY Change | ||
| Treasury Stock (at cost) | ||
| YoY Change | ||
| Treasury Stock Shares | ||
| Shareholders Equity | $42.47M | $61.57M |
| YoY Change | ||
| Total Liabilities & Shareholders Equity | $46.44M | $68.20M |
| YoY Change | -31.9% | 169.57% |
Cashflow Statement
| Concept | 2015 Q2 | 2014 Q2 |
|---|---|---|
| OPERATING ACTIVITIES | ||
| Net Income | -$5.684M | -$3.645M |
| YoY Change | 55.94% | -168.3% |
| Depreciation, Depletion And Amortization | $200.0K | $190.0K |
| YoY Change | 5.26% | -52.5% |
| Cash From Operating Activities | -$4.260M | -$4.240M |
| YoY Change | 0.47% | -137.42% |
| INVESTING ACTIVITIES | ||
| Capital Expenditures | $0.00 | -$10.00K |
| YoY Change | -100.0% | |
| Acquisitions | ||
| YoY Change | ||
| Other Investing Activities | ||
| YoY Change | ||
| Cash From Investing Activities | $0.00 | -$10.00K |
| YoY Change | -100.0% | |
| FINANCING ACTIVITIES | ||
| Cash Dividend Paid | ||
| YoY Change | ||
| Common Stock Issuance & Retirement, Net | ||
| YoY Change | ||
| Debt Paid & Issued, Net | ||
| YoY Change | ||
| Cash From Financing Activities | 30.00K | 20.00K |
| YoY Change | 50.0% | -99.77% |
| NET CHANGE | ||
| Cash From Operating Activities | -4.260M | -4.240M |
| Cash From Investing Activities | 0.000 | -10.00K |
| Cash From Financing Activities | 30.00K | 20.00K |
| Net Change In Cash | -4.230M | -4.230M |
| YoY Change | 0.0% | -121.09% |
| FREE CASH FLOW | ||
| Cash From Operating Activities | -$4.260M | -$4.240M |
| Capital Expenditures | $0.00 | -$10.00K |
| Free Cash Flow | -$4.260M | -$4.230M |
| YoY Change | 0.71% | -137.33% |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2015Q3 | dei |
Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
|
27164875 | shares |
| CY2014Q2 | us-gaap |
Shares Issued Price Per Share
SharesIssuedPricePerShare
|
11.00 | |
| CY2014Q2 | us-gaap |
Stockholders Equity
StockholdersEquity
|
61568000 | |
| CY2014Q2 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
62812000 | |
| CY2015Q2 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
100000000 | shares |
| CY2015Q2 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | shares |
| CY2015Q2 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
22836919 | shares |
| CY2015Q2 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
| CY2015Q2 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
5000000 | shares |
| CY2015Q2 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | shares |
| CY2015Q2 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
22836919 | shares |
| CY2015Q2 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.001 | |
| CY2015Q2 | us-gaap |
Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
|
913000 | |
| CY2015Q2 | us-gaap |
Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
|
133021000 | |
| CY2015Q2 | us-gaap |
Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
|
543000 | |
| CY2015Q2 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
41000 | |
| CY2015Q2 | us-gaap |
Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
|
2098000 | |
| CY2015Q2 | us-gaap |
Stockholders Equity
StockholdersEquity
|
42470000 | |
| CY2015Q2 | us-gaap |
Operating Leases Future Minimum Payments Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear
|
445000 | |
| CY2015Q2 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
303000 | |
| CY2015Q2 | us-gaap |
Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
|
3150000 | |
| CY2015Q2 | us-gaap |
Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
|
732000 | |
| CY2015Q2 | us-gaap |
Deferred Revenue Current
DeferredRevenueCurrent
|
89000 | |
| CY2015Q2 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
711000 | |
| CY2015Q2 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-90574000 | |
| CY2015Q2 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
46441000 | |
| CY2015Q2 | us-gaap |
Common Stock Value
CommonStockValue
|
23000 | |
| CY2015Q2 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
||
| CY2015Q2 | us-gaap |
Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
|
0 | |
| CY2015Q2 | us-gaap |
Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
|
0 | |
| CY2015Q2 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
3239000 | |
| CY2015Q2 | us-gaap |
Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
|
740000 | |
| CY2015Q2 | us-gaap |
Income Taxes Receivable
IncomeTaxesReceivable
|
250000 | |
| CY2015Q2 | us-gaap |
Assets
Assets
|
46441000 | |
| CY2015Q2 | us-gaap |
Restricted Cash And Investments Noncurrent
RestrictedCashAndInvestmentsNoncurrent
|
700000 | |
| CY2015Q2 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
1710000 | |
| CY2015Q2 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
||
| CY2015Q2 | us-gaap |
Assets Current
AssetsCurrent
|
44031000 | |
| CY2015Q2 | us-gaap |
Deferred Offering Costs
DeferredOfferingCosts
|
51000 | |
| CY2015Q2 | us-gaap |
Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
|
81000 | |
| CY2015Q2 | us-gaap |
Prepaid Insurance
PrepaidInsurance
|
423000 | |
| CY2015Q2 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
590000 | |
| CY2015Q2 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
43191000 | |
| CY2015Q2 | cara |
Prepaid Research And Development Expenses
PrepaidResearchAndDevelopmentExpenses
|
35000 | |
| CY2015Q2 | cara |
Accrued Research Projects
AccruedResearchProjects
|
1552000 | |
| CY2013Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
-54075000 | |
| CY2013Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
12357000 | |
| CY2014Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
100000000 | shares |
| CY2014Q4 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | shares |
| CY2014Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
22802039 | shares |
| CY2014Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
| CY2014Q4 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
5000000 | shares |
| CY2014Q4 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | shares |
| CY2014Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
22802039 | shares |
| CY2014Q4 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.001 | |
| CY2014Q4 | us-gaap |
Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
|
131840000 | |
| CY2014Q4 | us-gaap |
Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
|
504000 | |
| CY2014Q4 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
112000 | |
| CY2014Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
51662000 | |
| CY2014Q4 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
266000 | |
| CY2014Q4 | us-gaap |
Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
|
1946000 | |
| CY2014Q4 | us-gaap |
Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
|
874000 | |
| CY2014Q4 | us-gaap |
Deferred Revenue Current
DeferredRevenueCurrent
|
1452000 | |
| CY2014Q4 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
515000 | |
| CY2014Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-80201000 | |
| CY2014Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
55934000 | |
| CY2014Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
23000 | |
| CY2014Q4 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
||
| CY2014Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
3398000 | |
| CY2014Q4 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
||
| CY2014Q4 | us-gaap |
Income Taxes Receivable
IncomeTaxesReceivable
|
200000 | |
| CY2014Q4 | us-gaap |
Assets
Assets
|
55934000 | |
| CY2014Q4 | us-gaap |
Restricted Cash And Investments Noncurrent
RestrictedCashAndInvestmentsNoncurrent
|
700000 | |
| CY2014Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
2084000 | |
| CY2014Q4 | us-gaap |
Assets Current
AssetsCurrent
|
53150000 | |
| CY2014Q4 | us-gaap |
Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
|
18000 | |
| CY2014Q4 | us-gaap |
Prepaid Insurance
PrepaidInsurance
|
92000 | |
| CY2014Q4 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
287000 | |
| CY2014Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
52663000 | |
| CY2014Q4 | cara |
Prepaid Research And Development Expenses
PrepaidResearchAndDevelopmentExpenses
|
177000 | |
| CY2014Q4 | cara |
Accrued Research Projects
AccruedResearchProjects
|
549000 | |
| us-gaap |
Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
|
-7330000 | ||
| us-gaap |
Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
|
0 | shares | |
| us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.37 | ||
| us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
1078011 | shares | |
| us-gaap |
Incremental Common Shares Attributable To Conversion Of Preferred Stock
IncrementalCommonSharesAttributableToConversionOfPreferredStock
|
0 | shares | |
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
|
0.71 | pure | |
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
|
0.00 | pure | |
| us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
19150412 | shares | |
| us-gaap |
Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
|
0 | shares | |
| us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
19150412 | shares | |
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
|
0.0180 | pure | |
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
|
0.0272 | pure | |
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
|
0.65 | pure | |
| us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
19150412 | shares | |
| us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
6000 | ||
| us-gaap |
Net Income Loss
NetIncomeLoss
|
-7028000 | ||
| us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
29000 | ||
| us-gaap |
Revenues
Revenues
|
1138000 | ||
| us-gaap |
Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
|
78000 | ||
| us-gaap |
Stock Issued During Period Value Conversion Of Convertible Securities Net Of Adjustments
StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments
|
65586000 | ||
| us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
809000 | ||
| us-gaap |
Increase Decrease In Income Taxes Receivable
IncreaseDecreaseInIncomeTaxesReceivable
|
-4000 | ||
| us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
56247000 | ||
| us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
561000 | ||
| us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-7133000 | ||
| us-gaap |
Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
|
480000 | ||
| us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-7055000 | ||
| us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
-27000 | ||
| us-gaap |
Share Based Compensation
ShareBasedCompensation
|
809000 | ||
| us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1
SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
|
809000 | ||
| us-gaap |
Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
|
7003000 | ||
| us-gaap |
Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
|
-406000 | ||
| us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
50455000 | ||
| us-gaap |
Operating Expenses
OperatingExpenses
|
8271000 | ||
| us-gaap |
Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
|
-6000 | ||
| us-gaap |
Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
|
57791000 | ||
| us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
5401000 | ||
| us-gaap |
Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
|
69000 | ||
| us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
29000 | ||
| us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
2870000 | ||
| us-gaap |
Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
|
65586000 | ||
| us-gaap |
Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
|
57762000 | ||
| us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
393000 | ||
| cara |
Collaborative Revenue
CollaborativeRevenue
|
677000 | ||
| cara |
Deferred Rent Liability Benefit
DeferredRentLiabilityBenefit
|
130000 | ||
| cara |
Clinical Compound Revenue
ClinicalCompoundRevenue
|
159000 | ||
| cara |
Noncash Or Part Noncash Unpaid Initial Public Offering Issuance Costs
NoncashOrPartNoncashUnpaidInitialPublicOfferingIssuanceCosts
|
50000 | ||
| cara |
License And Milestone Fees Revenue
LicenseAndMilestoneFeesRevenue
|
302000 | ||
| cara |
Non Cash Or Part Non Cash Prepaid Initial Public Offering Costs Offset Against Proceeds Of Initial Public Offering
NonCashOrPartNonCashPrepaidInitialPublicOfferingCostsOffsetAgainstProceedsOfInitialPublicOffering
|
1465000 | ||
| dei |
Document Fiscal Period Focus
DocumentFiscalPeriodFocus
|
Q2 | ||
| us-gaap |
Nature Of Operations
NatureOfOperations
|
<div> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td valign="top" width="4%" align="left"><b>1.</b></td> <td valign="top" align="left"><b>Business</b></td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> Cara Therapeutics, Inc. (the “Company”, “we”, “our” or “us”) is a clinical-stage biopharmaceutical corporation formed on July 2, 2004. The Company is focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors. The Company’s primary activities to date have been organizing and staffing the company, developing its product candidates, including conducting preclinical studies and clinical trials of CR845-based product candidates and raising capital.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> As of June 30, 2015, the Company has raised aggregate net proceeds of approximately $129,600 from several rounds of equity financing, including its initial public offering, and the issuance of debt. In addition, the Company received $30,100 under its license agreements for CR845, primarily with Maruishi Pharmaceutical Co. Ltd. (“Maruishi”) and Chong Kun Dang Pharmaceutical Corp. (“CKD”), and an earlier product candidate for which development efforts ceased in 2007. Included in those aforementioned payments pursuant to license agreements, in April 2013, the Company received $15,000 as an upfront payment, and in August 2014, the Company received an additional $480 related to achievement of a milestone in connection with the license of rights to CR845 in Japan to Maruishi. In 2012, the Company received aggregate upfront and milestone payments of $1,190 pursuant to a license agreement with CKD, in connection with the license of rights to CR845 in South Korea. The Company has incurred substantial losses and negative cash flows from operating activities in nearly every fiscal period since inception, and expects operating losses and negative cash flows to continue into the foreseeable future.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> As of June 30, 2015, the Company had unrestricted cash and cash equivalents of $43,191 and an accumulated deficit of $90,574. The Company had net cash used in operating activities of $9,495 and $7,330 for the six months ended June 30, 2015 and 2014, respectively. The Company expects that cash and cash equivalents at June 30, 2015 will be sufficient to fund its operations beyond one year. The Company recognized net losses of $5,684 and $10,373 for the three and six months ended June 30, 2015, respectively, and $3,645 and $7,028 for the three and six months ended June 30, 2014, respectively, and expects to incur additional losses for the full year ending December 31, 2015.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> In order to fund future operations, including clinical trials, the Company filed a shelf registration statement on Form S-3 (File No. 333-203072), which the Securities and Exchange Commission (“SEC”) declared effective on May 13, 2015. The shelf registration statement provides for the offering of up to $150,000 of common stock, preferred stock, debt securities, warrants or any combination thereof. The Company may offer the securities under its shelf registration statement from time to time in response to market conditions or other circumstances if it believes such a plan of financing is in the best interests of its stockholders.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> On August 4, 2015, the Company closed an underwritten public offering of 4,327,956 shares of its common stock at a public offering price of $18.60 per share pursuant to its shelf registration statement, receiving net proceeds of approximately $75,060, after deducting the underwriting discounts and commissions and estimated offering expenses payable by the Company (see Note 11, <i>Subsequent Event</i>, of Notes to Condensed Financial Statements).</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> The Company is subject to risks common to other life science companies including, but not limited to, uncertainty of product development and commercialization, lack of marketing and sales history, development by its competitors of new technological innovations, dependence on key personnel, market acceptance of products, product liability protection of proprietary technology, ability to raise additional financing, and compliance with Food and Drug Administration (“FDA”) and other government regulations. If the Company does not successfully commercialize any of its product candidates, it will be unable to generate recurring product revenue or achieve profitability.</p> </div> | ||
| us-gaap |
Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
|
-9495000 | ||
| us-gaap |
Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
|
0 | shares | |
| dei |
Document Fiscal Year Focus
DocumentFiscalYearFocus
|
2015 | ||
| dei |
Amendment Flag
AmendmentFlag
|
false | ||
| us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.45 | ||
| us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
1583480 | shares | |
| dei |
Document Type
DocumentType
|
10-Q | ||
| dei |
Entity Central Index Key
EntityCentralIndexKey
|
0001346830 | ||
| dei |
Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
|
2004-07-02 | ||
| dei |
Entity Filer Category
EntityFilerCategory
|
Non-accelerated Filer | ||
| us-gaap |
Incremental Common Shares Attributable To Conversion Of Preferred Stock
IncrementalCommonSharesAttributableToConversionOfPreferredStock
|
0 | shares | |
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
|
0.67 | pure | |
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
|
0.00 | pure | |
| dei |
Current Fiscal Year End Date
CurrentFiscalYearEndDate
|
--12-31 | ||
| dei |
Entity Registrant Name
EntityRegistrantName
|
Cara Therapeutics, Inc. | ||
| us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
22818601 | shares | |
| us-gaap |
Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
|
0 | shares | |
| us-gaap |
Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
|
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 18pt"> <i>Reclassifications</i></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> Certain revenue amounting to $132 and $159 within the Statements of Operations for the three and six months ended June 30, 2014, respectively, has been reclassified from Collaborative revenue to Clinical compound revenue to conform to the current year presentation.</p> </div> | ||
| us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
22818601 | shares | |
| us-gaap |
Class Of Warrant Or Righst Date From Which Warrants Or Rights Exercisable
ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable
|
2014-07-31 | ||
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
|
0.0143 | pure | |
| dei |
Document Period End Date
DocumentPeriodEndDate
|
2015-06-30 | ||
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
|
0.0189 | pure | |
| us-gaap |
Use Of Estimates
UseOfEstimates
|
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 18pt"> <i>Use of Estimates</i></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> The preparation of financial statements in conformity with GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosure of contingent assets and liabilities, as of the date of the financial statements as well as the reported amounts of revenues and expenses during the reporting period. Actual results could differ materially from the Company’s estimates and assumptions. Significant estimates include useful lives of fixed assets, the periods over which certain revenues will be recognized, including licensing and collaborative revenue recognized from non-refundable up-front and milestone payments, the determination of prepaid research and development clinical costs and accrued research projects, the amount of non-cash compensation costs related to share-based payments to employees and non-employees and the periods over which those costs are expensed and the likelihood of realization of deferred tax assets.</p> </div> | ||
| dei |
Trading Symbol
TradingSymbol
|
CARA | ||
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
|
0.64 | pure | |
| us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
22818601 | shares | |
| us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
12000 | ||
| us-gaap |
Net Income Loss
NetIncomeLoss
|
-10373000 | ||
| us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
35000 | ||
| us-gaap |
Revenues
Revenues
|
1363000 | ||
| us-gaap |
Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
|
27000 | ||
| us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
1146000 | ||
| us-gaap |
Increase Decrease In Income Taxes Receivable
IncreaseDecreaseInIncomeTaxesReceivable
|
50000 | ||
| us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
303000 | ||
| us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-10450000 | ||
| us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-10423000 | ||
| us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1
SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
|
1146000 | ||
| us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
-50000 | ||
| us-gaap |
Share Based Compensation
ShareBasedCompensation
|
1146000 | ||
| us-gaap |
Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
|
-1363000 | ||
| us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
-9472000 | ||
| us-gaap |
Operating Expenses
OperatingExpenses
|
11813000 | ||
| us-gaap |
Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
|
-12000 | ||
| us-gaap |
Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
|
35000 | ||
| us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
8069000 | ||
| us-gaap |
Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
|
1204000 | ||
| us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
35000 | ||
| us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
3744000 | ||
| us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
386000 | ||
| cara |
Collaborative Revenue
CollaborativeRevenue
|
1363000 | ||
| cara |
Deferred Rent Liability Benefit
DeferredRentLiabilityBenefit
|
142000 | ||
| cara |
Percentage Of Research And Development Tax Credits Exchanged For Cash
PercentageOfResearchAndDevelopmentTaxCreditsExchangedForCash
|
0.65 | pure | |
| cara |
Aggregate Net Proceeds From Equity Financing And Issuance Of Debt
AggregateNetProceedsFromEquityFinancingAndIssuanceOfDebt
|
129600000 | ||
| cara |
Cash Received In Connection With License Agreements Including Upfront And Milestone Payments Received
CashReceivedInConnectionWithLicenseAgreementsIncludingUpfrontAndMilestonePaymentsReceived
|
30100000 | ||
| CY2014Q2 | us-gaap |
Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
|
0 | shares |
| CY2014Q2 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.16 | |
| CY2014Q2 | us-gaap |
Incremental Common Shares Attributable To Conversion Of Preferred Stock
IncrementalCommonSharesAttributableToConversionOfPreferredStock
|
0 | shares |
| CY2014Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
|
0.65 | pure |
| CY2014Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
|
0.00 | pure |
| CY2014Q2 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
22608324 | shares |
| CY2014Q2 | us-gaap |
Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
|
0 | shares |
| CY2014Q2 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
22608324 | shares |
| CY2014Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
|
0.0180 | pure |
| CY2014Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
|
0.0199 | pure |
| CY2014Q2 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
22608324 | shares |
| CY2014Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-3645000 | |
| CY2014Q2 | us-gaap |
Revenues
Revenues
|
960000 | |
| CY2014Q2 | us-gaap |
Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
|
56000 | |
| CY2014Q2 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-3712000 | |
| CY2014Q2 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-3656000 | |
| CY2014Q2 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
-11000 | |
| CY2014Q2 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1
SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
|
456000 | |
| CY2014Q2 | us-gaap |
Operating Expenses
OperatingExpenses
|
4672000 | |
| CY2014Q2 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
3200000 | |
| CY2014Q2 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
1472000 | |
| CY2014Q2 | cara |
Collaborative Revenue
CollaborativeRevenue
|
526000 | |
| CY2014Q2 | cara |
Clinical Compound Revenue
ClinicalCompoundRevenue
|
132000 | |
| CY2014Q2 | cara |
License And Milestone Fees Revenue
LicenseAndMilestoneFeesRevenue
|
302000 | |
| CY2015Q2 | us-gaap |
Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
|
0 | shares |
| CY2015Q2 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.25 | |
| CY2015Q2 | us-gaap |
Incremental Common Shares Attributable To Conversion Of Preferred Stock
IncrementalCommonSharesAttributableToConversionOfPreferredStock
|
0 | shares |
| CY2015Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
|
0.64 | pure |
| CY2015Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
|
0.00 | pure |
| CY2015Q2 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
22828612 | shares |
| CY2015Q2 | us-gaap |
Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
|
0 | shares |
| CY2015Q2 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
22828612 | shares |
| CY2015Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
|
0.0187 | pure |
| CY2015Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
|
0.0189 | pure |
| CY2015Q2 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
22828612 | shares |
| CY2015Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-5684000 | |
| CY2015Q2 | us-gaap |
Revenues
Revenues
|
874000 | |
| CY2015Q2 | us-gaap |
Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
|
13000 | |
| CY2015Q2 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-5732000 | |
| CY2015Q2 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-5719000 | |
| CY2015Q2 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
-35000 | |
| CY2015Q2 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1
SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
|
700000 | |
| CY2015Q2 | us-gaap |
Operating Expenses
OperatingExpenses
|
6606000 | |
| CY2015Q2 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
4684000 | |
| CY2015Q2 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
1922000 | |
| CY2015Q2 | cara |
Collaborative Revenue
CollaborativeRevenue
|
874000 |
